Jiangsu Hengrui Medicine Co., Ltd.
600276
Classement en actions
#544
Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged... Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
Prix de l'action
$6.89
Capitalisation boursière
$43.94B
Changement (1 jour)
-2.91%
Changement (1 an)
-24.78%
Pays
CN
Échange Jiangsu Hengrui Medicine Co., Ltd. (600276)
Catégorie
Healthcare
Revenus pour Jiangsu Hengrui Medicine Co., Ltd. (600276)
Revenus en Oct 2026 TTM : 0
Selon les derniers rapports financiers de Jiangsu Hengrui Medicine Co., Ltd., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Jiangsu Hengrui Medicine Co., Ltd. de 2001 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2025 | $4.49B | 17.17% |
| 2024 | $3.83B | 18.93% |
| 2023 | $3.22B | 4.52% |
| 2022 | $3.08B | -24.33% |
| 2021 | $4.08B | -4.00% |
| 2020 | $4.25B | 26.94% |
| 2019 | $3.34B | 32.08% |
| 2018 | $2.53B | 19.08% |
| 2017 | $2.13B | 33.09% |
| 2016 | $1.60B | 11.38% |
| 2015 | $1.43B | 19.24% |
| 2014 | $1.20B | 17.65% |
| 2013 | $1.02B | 17.33% |
| 2012 | $871.59M | 20.75% |
| 2011 | $721.81M | 27.25% |
| 2010 | $567.25M | 27.86% |
| 2009 | $443.66M | 26.53% |
| 2008 | $350.63M | 30.64% |
| 2007 | $268.38M | 47.29% |
| 2006 | $182.22M | 24.73% |
| 2005 | $146.10M | 5.58% |
| 2004 | $138.38M | 9.03% |
| 2003 | $126.92M | 38.95% |
| 2002 | $91.34M | 19.17% |
| 2001 | $76.65M | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | - |
IN
|
